Concepts (97)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, Optical Coherence | 7 | 2024 | 45 | 2.860 |
Why?
|
| Retina | 5 | 2019 | 61 | 2.640 |
Why?
|
| Visual Acuity | 6 | 2024 | 73 | 2.590 |
Why?
|
| Retinal Vessels | 2 | 2019 | 19 | 1.360 |
Why?
|
| Fluorescein Angiography | 5 | 2019 | 16 | 1.330 |
Why?
|
| Vitrectomy | 2 | 2024 | 9 | 1.170 |
Why?
|
| Basement Membrane | 1 | 2024 | 8 | 0.950 |
Why?
|
| Retinal Perforations | 1 | 2024 | 4 | 0.950 |
Why?
|
| Alzheimer Disease | 2 | 2018 | 327 | 0.940 |
Why?
|
| Meningocele | 1 | 2023 | 1 | 0.920 |
Why?
|
| Surgical Flaps | 1 | 2024 | 72 | 0.910 |
Why?
|
| Optic Nerve Diseases | 1 | 2023 | 19 | 0.890 |
Why?
|
| Optic Nerve | 2 | 2023 | 16 | 0.850 |
Why?
|
| Macular Edema | 2 | 2023 | 17 | 0.820 |
Why?
|
| Vision Disorders | 2 | 2018 | 23 | 0.790 |
Why?
|
| Macular Degeneration | 2 | 2018 | 22 | 0.720 |
Why?
|
| Choroid | 1 | 2019 | 4 | 0.700 |
Why?
|
| Choroidal Neovascularization | 1 | 2019 | 3 | 0.690 |
Why?
|
| Ophthalmology | 2 | 2024 | 7 | 0.680 |
Why?
|
| Retinal Diseases | 1 | 2019 | 20 | 0.670 |
Why?
|
| Anemia, Sickle Cell | 1 | 2019 | 45 | 0.660 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 1 | 2018 | 1 | 0.650 |
Why?
|
| Eye Infections, Viral | 1 | 2018 | 3 | 0.650 |
Why?
|
| Herpesvirus 1, Human | 1 | 2018 | 8 | 0.650 |
Why?
|
| Herpes Simplex | 1 | 2018 | 13 | 0.640 |
Why?
|
| Macula Lutea | 1 | 2018 | 9 | 0.620 |
Why?
|
| Peritoneal Dialysis | 1 | 2017 | 26 | 0.590 |
Why?
|
| Conjunctiva | 1 | 2017 | 4 | 0.580 |
Why?
|
| Eye Neoplasms | 1 | 2017 | 3 | 0.580 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2017 | 9 | 0.580 |
Why?
|
| Cornea | 1 | 2017 | 16 | 0.570 |
Why?
|
| Diabetic Retinopathy | 1 | 2017 | 65 | 0.570 |
Why?
|
| Colitis, Ulcerative | 1 | 2017 | 23 | 0.570 |
Why?
|
| Retinal Detachment | 3 | 2023 | 9 | 0.560 |
Why?
|
| Epithelial Cells | 1 | 2017 | 141 | 0.540 |
Why?
|
| Humans | 16 | 2024 | 32082 | 0.490 |
Why?
|
| Child, Preschool | 4 | 2019 | 1267 | 0.490 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2013 | 22 | 0.440 |
Why?
|
| Delivery of Health Care | 2 | 2024 | 160 | 0.440 |
Why?
|
| Female | 10 | 2024 | 19999 | 0.430 |
Why?
|
| Retrospective Studies | 5 | 2024 | 3505 | 0.420 |
Why?
|
| Guideline Adherence | 1 | 2013 | 120 | 0.420 |
Why?
|
| Kidney Failure, Chronic | 1 | 2017 | 543 | 0.420 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 69 | 0.420 |
Why?
|
| Child | 4 | 2019 | 2439 | 0.400 |
Why?
|
| Male | 9 | 2024 | 19202 | 0.390 |
Why?
|
| Brain | 1 | 2018 | 948 | 0.380 |
Why?
|
| Infant | 3 | 2019 | 1061 | 0.370 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 2263 | 0.370 |
Why?
|
| Adolescent | 4 | 2019 | 3568 | 0.360 |
Why?
|
| Internship and Residency | 1 | 2013 | 311 | 0.330 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2017 | 36 | 0.290 |
Why?
|
| Epiretinal Membrane | 1 | 2024 | 2 | 0.240 |
Why?
|
| Aged | 4 | 2024 | 10308 | 0.230 |
Why?
|
| Uncompensated Care | 1 | 2024 | 4 | 0.230 |
Why?
|
| Middle Aged | 4 | 2024 | 11834 | 0.220 |
Why?
|
| Treatment Outcome | 2 | 2024 | 3304 | 0.220 |
Why?
|
| Fundus Oculi | 1 | 2019 | 11 | 0.170 |
Why?
|
| Capillaries | 1 | 2019 | 24 | 0.170 |
Why?
|
| Hemoglobin, Sickle | 1 | 2019 | 8 | 0.170 |
Why?
|
| Eye Enucleation | 1 | 2019 | 4 | 0.170 |
Why?
|
| Paraffin Embedding | 1 | 2019 | 10 | 0.170 |
Why?
|
| Cryosurgery | 1 | 2019 | 20 | 0.160 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 1542 | 0.160 |
Why?
|
| Foscarnet | 1 | 2018 | 1 | 0.160 |
Why?
|
| Organ Size | 1 | 2019 | 218 | 0.160 |
Why?
|
| Fibrosis | 1 | 2019 | 120 | 0.160 |
Why?
|
| Laser Therapy | 1 | 2019 | 55 | 0.160 |
Why?
|
| Atrophy | 1 | 2018 | 46 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 1 | 2018 | 198 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2018 | 108 | 0.150 |
Why?
|
| Forecasting | 1 | 2018 | 142 | 0.150 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 2017 | 2 | 0.150 |
Why?
|
| Mesalamine | 1 | 2017 | 2 | 0.150 |
Why?
|
| Laser Coagulation | 1 | 2017 | 13 | 0.140 |
Why?
|
| Prednisone | 1 | 2017 | 61 | 0.140 |
Why?
|
| Drug Combinations | 1 | 2017 | 98 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 112 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 72 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2017 | 145 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 516 | 0.130 |
Why?
|
| Disease Progression | 1 | 2017 | 594 | 0.120 |
Why?
|
| Adult | 2 | 2018 | 9375 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2019 | 2282 | 0.110 |
Why?
|
| Academies and Institutes | 1 | 2013 | 5 | 0.110 |
Why?
|
| Cohort Studies | 1 | 2017 | 1816 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2013 | 164 | 0.100 |
Why?
|
| Oxidants | 1 | 2012 | 15 | 0.100 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2012 | 19 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 271 | 0.090 |
Why?
|
| United States | 2 | 2024 | 3975 | 0.090 |
Why?
|
| Charities | 1 | 2024 | 1 | 0.060 |
Why?
|
| Scleral Buckling | 1 | 2023 | 3 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 242 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2023 | 780 | 0.040 |
Why?
|
| Risk Factors | 1 | 2023 | 3880 | 0.030 |
Why?
|
| Animals | 1 | 2012 | 7510 | 0.010 |
Why?
|